To investigate soluble IL-2 receptor (sIL-2R) levels in nasal allergy, the sera and nasal secretions from patients with nasal allergy and from healthy subjects were subjected to a double-epitope enzyme-linked immunosorbent assay. Significant elevation of sIL-2R concentrations in the sera and nasal secretions was observed in the allergy patients (n 26) compared with those of healthy subjects (n 9). IL-2R-positive (CD25/) cells were observed in the crust formed in an allergic nasal mucosa. The concentration of sIL-2R in the sera correlated neither with the eosinophil count of the peripheral blood count nor with clinical severity. The concentration of sIL-2R in the nasal secretions was significantly higher compared with that in the sera from allergic patients (,O < 0.01), whereas no significant difference was observed between sIL-2R levels in the sera and nasal sections from normal subjects. These findings indicate that sIL-2R plays an essential role in allergic processes by regulating IL-2R-positive cells recruited into the nasal mucosa.
Results
Levels of sIL-2R in the sera: The mean (+ S.D.) values of serum slL-2R concentrations in the allergic patients and of the normal subjects were 513 + 171 U/ml and 310 + 137 U/ml, respectively. In patients with nasal allergy, the serum slL-2R concentration was significantly higher as compared with that of the normal subjects (p< 0.01, Fig. 1 ). However, there was no significant correlation between serum slL-2R concentration and clinical severity.
Levels of slL-2R in nasal secretions: The mean (+ S.D.)
values of slL-2R concentrations in the nasal secretions of the patients and of the normal subjects were 1 513 + 1 233 U/ml and 371 + 193 U/ml, respectively.
The concentration of slL-2R was significantly higher in the nasal secretions of nasal allergy patients compared with that of the normal subjects (p < 0.01). However, there was no significant correlation between the concentrations of slL-2R in the nasal secretions and clinical severity (Fig. 2) There was no significant correlation between slL-2R concentration in the nasal secretions and clinical severity.
detected in the nasal secretions was significantly higher than that in the serum (p < 0.01).
Presence of CD25 cells: CD25 cells were found in the nasal mucosa from the inferior turbinate of nasal allergy patients (Fig. 3 12 Furthermore, it has also been reported that rlL-2 administration as a part of immunotherapy for a malignant tumour induced marked eosinophilia. 14, 15 These data still suggest a positive relationship between IL-2 and eosinophil accumulation.
The mechanism of IL-2 induced eosinophil infiltration may possibly be explained by IL-5 derived from activated T cells. 16, 17 IL-5 is a potent and specific eosinophil growth factor, TM and significantly prolongs eosinophil survival. 19 IL-5 also enhances the expression of adhesion molecules on vascular endothelial cells, 2 and induces chemotaxis 21 and activation of eosinophils. 18 Therefore, CD25 cells stimulated by IL-2 might induce eosinophil infiltration in the nasal mucosa in conjunction with IL-5 released from mast cells following allergen challenge.
In conclusion, we measured slL-2R levels in the nasal secretions and sera from nasal allergy patients and healthy control subjects, and found elevated levels of sIL-2R concentration in both the nasal secretions and sera in the patients with nasal allergy.
Accumulation of CD25 cells was found in the allergic nasal mucosa by immunocytochemical examination. These results suggest that T cell activation is induced in nasal allergy, which results in persistent inflammation f the nose.
